Prolor Biotech Inc. (Bulletin Board: PBTH) (formerly Modigene) is set to begin the Phase I clinical trial of its flagship product, a long-acting human growth hormone drug, hGH-CTP. The trial will be conducted at the Sourasky Medical Center - Ichilov Hospital in Tel Aviv
Prolor had earlier said that it hoped to complete trial before the end of 2009 and complete the Phase II trial by mid-2010. Prolor president Shai Novik said that the trial is on 24 healthy individuals to test the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of the drug.
hGH-CTP aims to provide growth hormone deficient adults and children with the option to replace the multiple injections per week that are currently required with a once-weekly or bi-monthly injection.
Lire l'intégralité de l'article » (Source: article de Gali Weinreb @ Globes)
Anti Boycott Israel blog: hormone de croissance Prolor Biotech